FDAnews Drug Daily Bulletin

DEBIOPHARM, AURIGENE TIE UP TO DEVELOP SELECTIVE COMPOUNDS FOR IMMUNO-ONCOLOGY TARGETS

June 29, 2006
A A

The Switzerland-based Debiopharm Group (Debiopharm), a global independent biopharmaceutical development company specialising in oncology and serious medical conditions, and Aurigene Discovery Technologies Ltd (Aurigene), a Bangalore-based discovery services company, signed a research agreement to identify and develop compounds for two innovative immuno-oncology targets. Pharmabiz (http://pharmabiz.com/article/detnews.asp?articleid=33991ionid)